Aptose Biosciences Collaborates with NCI to Advance Tuspetinib in Precision Medicine Trials for AML and MDS

Novartis and PTC Therapeutics Forge $2.9 Billion Partnership for Huntington’s Drug PTC518

HCG and Accenture Partner to Transform Cancer Care with Advanced AI

GE HealthCare to Acquire Full Ownership of Nihon Medi-Physics, Expanding Molecular Imaging Leadership in Asia

Strand Life Sciences Unveils CancerSpot for Early Cancer Detection

Allink Biotherapeutics Secures $42 Million in Series A Financing to Accelerate Development of Next-Generation Oncology and Immunology Therapies

Apollo Cancer Centres Launch India’s First Lunglife Screening Programme for Early Detection of Lung Cancer

Agilus Diagnostics Unveils Claudin 18.2 Test: A Breakthrough in Cancer Care

Leqembi® Launched in South Korea for Early Alzheimer’s Disease Treatment

QIAGEN Expands QIAstat-Dx Operations with New Facility in Barcelona

SunAct Cancer Institute Partners with Abgentil Biomedical to Revolutionize Cancer Treatment in India

Dr. Reddy’s Launches Toripalimab in India for Advanced Nasopharyngeal Carcinoma

European Commission Approves Kisqali® for HR+/HER2- Early Breast Cancer at High Risk of Recurrence

European Commission Approves TEVIMBRA® for First-Line Treatment of ESCC and G/GEJ Adenocarcinoma

ICPO Theranostics Virtual Summit 2024: Advancing a New Era in Precision Oncology

Home
/
update
/
details

Strand Life Sciences Unveils CancerSpot for Early Cancer Detection

NextEdge Admin

01 Dec 2024

1 min 43 sec

Early Cancer Detection,DNA methylation,Liquid biopsy

Strand Life Sciences, a Reliance Industries subsidiary, has introduced CancerSpot, an advanced blood-based test designed for the early detection of multiple cancer types. Utilizing cutting-edge methylation profiling technology, CancerSpot identifies tumor DNA fragments in a simple blood sample, enabling non-invasive and precise detection of cancers at their early stages.

Developed after years of rigorous research, CancerSpot employs state-of-the-art genome sequencing and analysis to pinpoint DNA methylation patterns indicative of cancer. This innovative approach underscores Strand’s commitment to revolutionizing healthcare in India through genomic advancements.

“Cancer is a leading cause of morbidity and mortality in India, imposing significant social, psychological, and economic burdens,” said Isha Ambani Piramal, a Reliance Industries board member. The launch of CancerSpot is a key step in addressing these challenges, aligning with the company’s vision to integrate cutting-edge genomics into transformative healthcare solutions.

With cancer rates on the rise, CancerSpot offers a timely and crucial tool to improve early detection and outcomes, reflecting Strand Life Sciences’ dedication to leveraging genomic innovation to combat the growing cancer burden in India,